Antimicrobial utilization among hospitalized patients according to WHO AWaRe Classification: results from a multicentre point prevalence survey in Saudi Arabia
Abstract
BACKGROUND
Antimicrobial resistance (AMR) threatens global health by reducing the efficacy of common infection treatments. This study examines antimicrobial use in Saudi Arabian hospitals, identifies influencing factors, and proposes interventions using the World Health Organization's (WHO) Access, Watch, Reserve (AWaRe) classification system.
METHODS
A cross-sectional, multicentre point prevalence survey (PPS) of antimicrobial utilization was conducted in 10 hospitals across 6 regions of Saudi Arabia September 2023. All inpatients receiving antimicrobials on the PPS day were included. Data collection utilized the Global PPS tool developed by the University of Antwerp, Belgium.
RESULTS
Among 2,890 inpatients, 766 (26.5%) were prescribed at least one antimicrobial, resulting in a total of 982 prescriptions. The primary indications for these antimicrobials were community acquired infections (37.1%), Healthcare associated infections (35.9%), surgical prophylaxis (15.4%), unknown reasons (8.7%), medical prophylaxis (2.5%), and other reasons (0.3%). The most common reasons for antimicrobial use included pneumonia or lower respiratory tract infections (16.1%), skin and soft tissue infections (11%), and bacteraemia (8.9%). The most frequently prescribed antimicrobial classes were penicillins with beta-lactamase inhibitors (18.5%), carbapenems (15.7%), and third-generation cephalosporins (11.1%). Most of the antimicrobials (66.3%) were classified as Watch antimicrobials, followed by…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.